GlycoFlux™ human AGL overexpression HEK293T cell line is a stable cell line engineered to express AGL, the glycogen debranching enzyme with dual 4-α-glucanotransferase and amylo-1,6-glucosidase activities. Defects cause glycogen storage disease type III, marked by hepatomegaly, hypoglycemia, and myopathy. This model enables research into glycogen degradation, liver and muscle metabolism, and therapeutic strategies for glycogen storage disorders.

Product Type

Overexpression Cell Lines

Species

Human

Cell Morphology

Epithelial-like, adherent

Passage Ratio

1:2~1:4

Cell Line

HEK293T

Lineage

Embryonic kidney

Specification

Cell Viability

>90%

Sterility Test

The sterility test indicated an absence of microbial growth.

Identity Test

STR identification

Mycoplasma Test

Negative

Virus Test

Negative for HIV, HBV and HCV.

Genetic Stability Testing

We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.

Validation

qPCR, Sanger Sequencing

Culture Medium

DMEM & FBS & Penicillin/Streptomycin

Application

Mechanistic studies; Exploration of glycosylation and signaling pathways in cancer, metabolic, and immune-related diseases; Drug target validation and other functional assays.

Size

1 M cells/vial*2

Product Format

Frozen

Shipping

Dry ice

Availability Status

Made to order

Handling Notes

Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.

Product Disclaimer

This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target Information

Target

AGL

Full Name

Amylo-Alpha-1, 6-Glucosidase, 4-Alpha-Glucanotransferase

Alternative Name

GDE

Location

1p21.2

Gene ID

178

Summary

Glycogen debranching enzyme is involved in glycogen breakdown, with 4-alpha-glucotransferase and amylo-1,6-glucosidase activities. Mutations in this gene lead to glycogen storage disease, with clinical variability potentially due to alternative splicing in different tissues.

GlycoFlux™ Human AGL Overexpression Raji Cell Line (CAT#: GLJF-0925-JF918)
GlycoErase™ AGL Knockout Glycoengineered Cell (CAT#: GLJF-0825-JF3)
GlycoErase™ AGL Knockout HEK293T Cell Line (CAT#: GLJF-0825-JF492)
GlycoFlux™ Human AGL Overexpression HEK293 Cell Line (CAT#: GLJF-0925-JF376)
GlycoFlux™ Human AGL Overexpression Jurkat Cell Line (CAT#: GLJF-0925-JF724)
GlycoFlux™ Human AGL Overexpression Glycoengineered Cell (CAT#: GLJF-0925-JF3)
GlycoErase™ AGL Knockout CHO-K1 Cell Line (CAT#: GLJF-0825-JF260)
GlycoErase™ AGL Knockout Jurkat Cell Line (CAT#: GLJF-0825-JF724)

For Research Use Only.

Online Inquiry